ZA200510170B - Method of reducing the harmful effects of orally or transdermally delivered nicotine - Google Patents

Method of reducing the harmful effects of orally or transdermally delivered nicotine

Info

Publication number
ZA200510170B
ZA200510170B ZA200510170A ZA200510170A ZA200510170B ZA 200510170 B ZA200510170 B ZA 200510170B ZA 200510170 A ZA200510170 A ZA 200510170A ZA 200510170 A ZA200510170 A ZA 200510170A ZA 200510170 B ZA200510170 B ZA 200510170B
Authority
ZA
South Africa
Prior art keywords
orally
reducing
harmful effects
transdermally delivered
delivered nicotine
Prior art date
Application number
ZA200510170A
Inventor
Conkling Mark
Original Assignee
Vector Tobacco Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vector Tobacco Ltd filed Critical Vector Tobacco Ltd
Publication of ZA200510170B publication Critical patent/ZA200510170B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/20—Biochemical treatment
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A24B15/243—Nicotine
    • A—HUMAN NECESSITIES
    • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
    • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
    • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
    • A24B15/18—Treatment of tobacco products or tobacco substitutes
    • A24B15/24—Treatment of tobacco products or tobacco substitutes by extraction; Tobacco extracts
    • A24B15/241—Extraction of specific substances
    • A24B15/245—Nitrosamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8243—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
ZA200510170A 2003-06-04 2005-12-14 Method of reducing the harmful effects of orally or transdermally delivered nicotine ZA200510170B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47594503P 2003-06-04 2003-06-04

Publications (1)

Publication Number Publication Date
ZA200510170B true ZA200510170B (en) 2006-11-29

Family

ID=33551567

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200510170A ZA200510170B (en) 2003-06-04 2005-12-14 Method of reducing the harmful effects of orally or transdermally delivered nicotine

Country Status (10)

Country Link
US (1) US20060237025A1 (en)
EP (1) EP1628681A4 (en)
JP (1) JP2007528204A (en)
KR (1) KR20060032141A (en)
CN (1) CN1812811A (en)
AR (1) AR044599A1 (en)
AU (1) AU2004251635A1 (en)
CA (1) CA2527648A1 (en)
WO (1) WO2005000352A1 (en)
ZA (1) ZA200510170B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ564025A (en) 2005-05-11 2012-03-30 Vector Tobacco Inc Reduced risk tobacco products and methods of making same
MX2009012842A (en) * 2007-06-01 2009-12-11 Syngenta Participations Ag Methods for the commercial production of transgenic plants.
US7667106B2 (en) 2007-11-06 2010-02-23 Alliance One International, Inc. Tobacco cultivar ‘AOB 175’
US7665472B2 (en) * 2007-11-06 2010-02-23 Alliance One International, Inc. Tobacco cultivar AOB 175 and products therefrom
WO2010046422A2 (en) 2008-10-22 2010-04-29 Basf Se Use of auxin type herbicides on cultivated plants
WO2010046423A2 (en) 2008-10-22 2010-04-29 Basf Se Use of sulfonylurea herbicides on cultivated plants
JP2015532274A (en) 2012-10-01 2015-11-09 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ Use of N-thio-anthranilamide compounds in cultivated plants
WO2014079820A1 (en) 2012-11-22 2014-05-30 Basf Se Use of anthranilamide compounds for reducing insect-vectored viral infections
CN103005702B (en) * 2012-12-12 2015-03-18 广东中烟工业有限责任公司 Design method of less harmful cigarette based on harm index under deep smoking
CN103005703B (en) * 2012-12-12 2015-04-15 广东中烟工业有限责任公司 Cigarette designing method based on smoke perniciousness index
CN102940310B (en) * 2012-12-12 2015-08-05 广东中烟工业有限责任公司 A kind of method of adjustment based on each component in the Cigarette design of N-nitrosamine burst size
EP3028573A1 (en) 2014-12-05 2016-06-08 Basf Se Use of a triazole fungicide on transgenic plants
WO2016091674A1 (en) 2014-12-12 2016-06-16 Basf Se Use of cyclaniliprole on cultivated plants
CA2980505A1 (en) 2015-04-07 2016-10-13 Basf Agrochemical Products B.V. Use of an insecticidal carboxamide compound against pests on cultivated plants
EP3338552A1 (en) 2016-12-21 2018-06-27 Basf Se Use of a tetrazolinone fungicide on transgenic plants
WO2020003363A1 (en) * 2018-06-25 2020-01-02 学校法人近畿大学 Nutrition supplement or pharmaceutical composition for preventing deterioration in blood vessels due to the impact of ingesting nicotine
JP2022552261A (en) * 2019-10-10 2022-12-15 アルトリア クライアント サーヴィシーズ リミテッド ライアビリティ カンパニー Compositions and Methods Based on QPT Engineering for Making Tobacco Plants and Tobacco Products with Altered Alkaloid Levels
CN113528537A (en) * 2021-08-11 2021-10-22 云南省烟草农业科学研究院 NtQPT2 gene mutant for reducing nicotine content in tobacco leaves and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005646A1 (en) * 1991-09-13 1993-04-01 Technology Management Services, S.A. Reduction of nicotine levels in tobacco
AU4991500A (en) * 1999-05-06 2000-11-21 Michael Timko Regulation of gene expression in tobacco for manipulation of plant growth and secondary metabolism
ATE360707T1 (en) * 2000-02-07 2007-05-15 Remedios Cristobal Guiller Dos BIOMOLECULAR TOXICITY TEST
JP2004507250A (en) * 2000-08-30 2004-03-11 ノース・キャロライナ・ステイト・ユニヴァーシティ Transgenic plants containing molecular decoys that alter protein content
WO2002037990A2 (en) * 2000-11-10 2002-05-16 Vector Tobacco Ltd. Method and product for removing carcinogens from tobacco smoke
US20060157072A1 (en) * 2001-06-08 2006-07-20 Anthony Albino Method of reducing the harmful effects of orally or transdermally delivered nicotine
SG132542A1 (en) * 2001-06-08 2007-06-28 Vector Tobacco Ltd Modifying nicotine and nitrosamine levels in tobacco
EP1441603A2 (en) * 2001-11-09 2004-08-04 Vector Tobacco Inc. Method and composition for mentholation of charcoal filtered cigarettes
WO2003086076A1 (en) * 2002-04-09 2003-10-23 Vector Tobacco Ltd. Tobacco having reduced nicotine and nitrosamines
US20050066986A1 (en) * 2003-09-30 2005-03-31 Nestor Timothy Brian Smokable rod for a cigarette

Also Published As

Publication number Publication date
US20060237025A1 (en) 2006-10-26
AR044599A1 (en) 2005-09-21
AU2004251635A1 (en) 2005-01-06
JP2007528204A (en) 2007-10-11
EP1628681A4 (en) 2009-07-15
KR20060032141A (en) 2006-04-14
WO2005000352A1 (en) 2005-01-06
CA2527648A1 (en) 2005-01-06
CN1812811A (en) 2006-08-02
EP1628681A1 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
ZA200510170B (en) Method of reducing the harmful effects of orally or transdermally delivered nicotine
AU2003249244A1 (en) Methods for the treatment of neoplasms
IL189657A (en) Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
EP1617805A4 (en) Methods of preventing or treating respiratory conditions
HK1103631A1 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
HUP0302739A3 (en) Method for the treatment of tobacco
AU2001285747A1 (en) Method for the treatment of tobacco
HK1083732A1 (en) Compounds for the treatment of tobacco dependence and withdrawal
EP1551388A4 (en) Compounds useful for the treatment of cancer, compositions thereof and methods therewith
HK1104800A1 (en) Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
GB0306309D0 (en) Method of treatment
GB0302572D0 (en) Method of treatment
EP1646640A4 (en) Method for the preparation of highly pure 1-androstene derivatives
IL166062A0 (en) Compositions and methods for therapeutic treatment
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
GB0221712D0 (en) Methods of treatment
GB0400094D0 (en) The method of treating tuberculosis
IL172528A0 (en) Surface treatment of sars-infected lungs
GB0213198D0 (en) Method of treatment
AU2003293714A1 (en) Methods for the treatment of chronic pain and compositions therefor
GB0207091D0 (en) Method of treatment
AU2003902314A0 (en) Method of treatment of autonomic neuropathy
GB0223254D0 (en) Methods of treatment
GB0208783D0 (en) Methods of treatment
GB0302657D0 (en) Method of treatment